started · updated
Caribou Biosciences halts CAR-T programs and explores strategic alternatives
Caribou Biosciences, a biotechnology company co-founded by Nobel laureate Jennifer Doudna, has announced it is discontinuing the development of two allogeneic CRISPR-based CAR-T programs: vispa-cel and CB-011.
CEO Rachel Haurwitz stated that the company was unable to secure the necessary funding to support a late-stage Phase 3 clinical trial for vispa-cel, which was intended for patients with advanced B-cell non-Hodgkin lymphoma. The decision follows difficult financing conditions for allogeneic CAR-T therapies.
In response to these challenges, the company's board of directors has initiated a strategic review to explore alternatives, including potential mergers, acquisitions, or the combination of business units. Wedbush Securities has been appointed as the exclusive financial advisor for this process. Caribou also plans to undergo significant workforce reductions, expected to be largely completed by the fourth quarter of 2026.
Entities
Caribou Biosciences · Jennifer Doudna · Rachel Haurwitz · Wedbush Securities